Anecortave Acetate Versus Placebo in AMD Patients Following PDT
Phase 2
Completed
- Conditions
- AMD
- Registration Number
- NCT00346866
- Lead Sponsor
- Alcon Research
- Brief Summary
The purpose of this study was to evaluate the efficacy of anecortave acetate for depot suspension (30 mg and 15 mg) plus PDT versus PDT alone with respect to maintenance of visual acuity in patients with wet AMD.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 136
Inclusion Criteria
- AMD disease
Exclusion Criteria
- Age
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Mean change from the baseline in logMAR visual acuity score at Month 6
- Secondary Outcome Measures
Name Time Method % patients who maintained vision, number of months of angiographic evidence of needing PDT re-treatment, and mean lesion sizes for the total choroidal neovascularization (CNV) and the classic component to the total CNV.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie anecortave acetate's anti-angiogenic effects in wet AMD?
How does anecortave acetate compare to anti-VEGF therapies in AMD patients post-PDT?
Are there specific biomarkers that predict response to anecortave acetate in AMD?
What are the long-term adverse events associated with anecortave acetate depot suspension?
What combination therapies are being explored for AMD alongside anecortave acetate?
Trial Locations
- Locations (1)
Facility
🇺🇸Beachwood, Ohio, United States
Facility🇺🇸Beachwood, Ohio, United States